Fresenius: latest news - GoINPHARMA
Wednesday, 17 October 2018 - 13:44

Fresenius

Fresenius abandons $4.3bn acquisition of Akorn

Fresenius has announced today what everyone dreaded. The Bad Homburg (Frankfurt)-based group has informed in a press release it will terminate the program to acquire the US-based Akorn. Fresenius has stated that there are no guarantees for an acquisition, since…

Fresenius keeps expanding in South America: 2 clinics acquired

Germany-based Fresenius seems unstoppable and determined to grow in South America through takeovers. The Brazilian financial portal Valor Economico has reported today that Fresenius has acquired Medservi and Unidade de Dialise de Transplante, two clinics for dialysis. Both companies are…

Acquisition of Akorn by Fresenius at risk: Akorn sinks, -33%

German healthcare group Fresenius yesterday announced that it is investigating alleged breaches of FDA data integrity requirements relating to product development by Akorn. Fresenius acquired US-based Akorn one year ago for $4.3bn including debt. Should investigation confirm Fresenius’ suspicions before…

Fresenius closer and closer to marketing biosimilars

Fresenius yesterday took the opportunity to demonstrate to investors and shareholders that purchasing Merck KGaA’s biosimilars portfolio has been a wise decision. Indeed, Fresenius Kabi yesterday submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for its biosimilar…

Fresenius Kabi announces new expansion plans resulting in 700 new jobs

Germany-based Fresenius Kabi has announced over the last few days new expansion plans expected to result in 705 new jobs. Specifically, the company has announced it would invest $100m in its Wilson, North Carolina plant, manufacturing sterile injectables. The investment…

The recent acquisitions underlying Fresenius’ record results (Q3 2017)

Stephan Sturm, CEO of Germany-based group Fresenius, this week announced the company’s third-quarter results: revenues increased by 15% to 17%, which met start-of-year predictions. This impressive growth is mainly due to the significant acquisitions recently carried out – Spain-based Quironsalud…

All-German M&A agreement between Fresenius and Merck KGaA

German’s Merck KGaA sold its biosimilars business to Fresenius. As part of the agreement, Fresenius will make an initial €170m payment, followed by additional payments of up to €500m, based on successful completion of precise milestones. Moreover, if the products…

Fresenius targeting US-based Akorn

German healthcare company Fresenius SE & Co KGaA announced on Friday evening that subsidiary Fresenius Kabi is in advanced talks to acquire US-based generic drugmaker Akorn. Akorn has a market value of approximately $3.7bn and five manufacturing sites in Decatur…